Abstract
In the definitive treatment of prostate cancer, patients at a high risk of nodal involvement have a better biochemical relapse free survival (bRFS) when receiving pelvic nodal irradiation with neoadjuvant and concurrent hormonal therapy. However, after radical prostatectomy, the consensus guidelines recommend irradiation only to the prostate bed even in patients at risk for lymph node metastasis. Here, we compared the bRFS among patients receiving whole pelvic radiotherapy (WPRT) versus prostate bed radiotherapy (PBRT) after radical prostatectomy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
